Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.
Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.
Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.
Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.
NovaBay Pharmaceuticals (NBY) announces that its DERMAdoctor’s Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm has received the National Eczema Association’s Seal of Acceptance. This product is designed to alleviate eczema symptoms, benefiting approximately 31 million Americans affected by the condition. The balm includes 1% colloidal oatmeal and an advanced complex of ceramides. Dr. Audrey Kunin emphasizes the product's efficacy for both adults and children, with plans for an appearance on QVC in February 2022.
NovaBay Pharmaceuticals (NBY) announces CEO Justin Hall's letter to stockholders regarding the acquisition of DERMAdoctor. This strategic move is set to double NovaBay's revenues and expedite its path to profitability with expected annual revenues of $20 million. The acquisition enhances product offerings, particularly in the skincare market, which is projected to reach $185 billion by 2027. NovaBay plans to leverage DERMAdoctor's distribution networks to expand internationally. A Special Meeting of Stockholders is scheduled for December 17, 2021, to vote on proposals related to the $15 million financing for this acquisition.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced the acquisition of DERMAdoctor, enhancing its position in the skincare market. Avenova revenue increased by 16% year-over-year, with unit sales hitting an all-time high. The DERMAdoctor acquisition is expected to be accretive to earnings within a year, potentially doubling overall revenues. For Q3 2021, net product revenue was $1.8 million with an improved net loss of $2.3 million, or $0.05 per share. The company aims for profitability by the end of 2022, driven by strong growth in existing and new products.
NovaBay Pharmaceuticals (NBY) has completed its acquisition of DERMAdoctor, LLC, adding over 30 dermatologist-developed skincare products to its portfolio. This strategic move aims to generate synergies and drive growth across their combined businesses. An earnings call is scheduled for November 11, 2021, where the company will reveal third-quarter results and elaborate on the expected benefits from this acquisition. The firm is advised by Two Roads Advisors LLC during this transaction.
NovaBay Pharmaceuticals (NYSE American: NBY) has closed a $15.0 million private placement, enabling the acquisition of DERMAdoctor, LLC scheduled for November 5, 2021. CEO Justin Hall emphasized that this acquisition is pivotal for the company's strategy to diversify into the skincare market, leveraging DERMAdoctor's profitable track record and product pipeline. NovaBay aims to launch new products post-acquisition, enhancing its market position in dermatological products.
NovaBay Pharmaceuticals (NYSE American: NBY) announced a private placement to raise approximately $15 million by selling 15,000 shares of Series B Non-Voting Convertible Preferred Stock at $1,000 each, along with warrants for up to 37.5 million common shares at $0.53. This funding aims to finance the acquisition of DERMAdoctor, enhancing NovaBay's presence in the skincare market. The acquisition is expected to significantly increase the company's product offerings and approaches to profitability. The deal is set to close around November 2, 2021.
NovaBay Pharmaceuticals (NYSE American: NBY) has announced a conference call and webcast scheduled for September 29, 2021, at 4:30 p.m. ET to discuss its acquisition of DERMAdoctor. The event will include a slide presentation and is open for pre-registration. Participants can dial in from the U.S. or internationally to gain access. NovaBay focuses on anti-infective consumer products, while DERMAdoctor is recognized for its clinical skincare solutions. The call will also be archived for later accessibility until October 14, 2021.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Management is optimistic about future growth through both organic expansion and strategic acquisitions. CEO Justin Hall emphasizes the company's commitment to leveraging its commercial expertise. NovaBay focuses on differentiated anti-infective products, including Avenova®, CelleRx® Clinical Reset™, and NeutroPhase®, which utilize patented hypochlorous acid formulations known for their non-toxic and irritation-free properties.
NovaBay Pharmaceuticals (NYSE American: NBY) has announced a distribution agreement with Okra Limited to sell Zocular dry eye products through its physician-dispensed sales channel. These products are designed to complement NovaBay's Avenova, which is clinically proven to reduce bacterial load on eyelids, addressing the underlying cause of bacterial dry eye. Zocular offers an in-office procedure called ZEST, along with at-home care products such as ZocuWipe and ZocuFoam, aimed at providing effective treatment for dry eye sufferers.
